Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg with Active Juvenile Idiopathic Arthritis (JIA) The primary objective of this study is to evaluate the safety of adalimumab in subjects 2 to < 4 years of age and subjects age 4 and above that weigh < 15 kg with moderately to severely active polyart...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease Estudio de 26 semanas que compara el gel intestinal Levodopa-Carbidopa con el tratamiento médico óptimo sobre los síntomas no motores en pacientes con enfermedad de Parkinson avanzada The primary objective of this study is to examine the effect of LCIG relative to that of OMT on non motor symptoms associated with advanced Parkinson's disease. El objetivo principal del estudio...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC) To assess if the addition of oral veliparib to carboplatin and paclitaxel compared to carboplatin and paclitaxel alone in subjects with metastatic or advanced NSCLC will improve progression-free survi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis The objective of this study is to evaluate the efficacy and safety of adalimumab 40 mg given every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open-label safety ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection To: - Assess the durability of response for subjects who achieved SVR12 with a regimen including ABT-493 and/or ABT-530. - Assess the emergence and persistence of specific HCV amino acid variants a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection (Endurance-1) ● To show the non-inferiority of the SVR12 rates among mono-infected HCV GT1 DAA-naïve subjects (the percentage of subjects achieving a 12-week sustained virologic response, SVR12, [HCV RNA < LLOQ 12 ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults Un estudio para evaluar Ombitasvir/Paritaprevir/Ritonavir y Dasabuvir en pacientes adultos con infección por el virus de la Hepatitis C Genotipo 1 no tratados previamente ?The primary objective of this study is to assess the efficacy (the percentage of subjects achieving a 12-week sustained virologic response, SVR12 [HCV ribonucleic acid {RNA} < lower limit of quantifi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized, Open-Label, Multicenter Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers The primary objective of the study is to assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival compared to Investigator's choice of standard chemotherapy in c...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir in Adults with Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, with Severe Kidney Impairment or End-Stage Kidney Disease (RUBY-II) Estudio abierto para evaluar eficacia y seguridad de Ombitasvir/Paritaprevir/Ritonavir con o sin Dasabuvir en adultos con infección crónica por el virus de la Hepatitis C (VHC) de los genotipos 1a o 4 con insuficiencia renal grave o nefropatía terminal (RUBY-II) The primary objective of this study is to assess the safety and efficacy (the percentage of subjects achieving a 12-week sustained virologic response, SVR12 [HCV ribonucleic acid (RNA) < lower limit o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy with Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection HCV RNA early viral load decline in the plasma following combination of ombitasvir/ABT-450/r and dasabuvir administered with low dose, full dose, or no RBV in treatment-naive HCV genotype GT 1a-infect...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune